nodes	percent_of_prediction	percent_of_DWPC	metapath
Irbesartan—JUN—lung cancer	0.394	1	CbGaD
Irbesartan—JUN—Vinblastine—lung cancer	0.19	0.536	CbGbCtD
Irbesartan—PTGS1—Etoposide—lung cancer	0.0119	0.0336	CbGbCtD
Irbesartan—CYP2C9—Gefitinib—lung cancer	0.0112	0.0316	CbGbCtD
Irbesartan—CYP2C9—Teniposide—lung cancer	0.0109	0.0306	CbGbCtD
Irbesartan—CYP2D6—Gefitinib—lung cancer	0.0102	0.0289	CbGbCtD
Irbesartan—CYP2C8—Erlotinib—lung cancer	0.0095	0.0268	CbGbCtD
Irbesartan—CYP2C8—Paclitaxel—lung cancer	0.0087	0.0245	CbGbCtD
Irbesartan—CYP2D6—Vinorelbine—lung cancer	0.00789	0.0222	CbGbCtD
Irbesartan—CYP1A2—Erlotinib—lung cancer	0.00735	0.0207	CbGbCtD
Irbesartan—CYP3A4—Topotecan—lung cancer	0.00712	0.0201	CbGbCtD
Irbesartan—CYP2C8—Etoposide—lung cancer	0.00687	0.0194	CbGbCtD
Irbesartan—CYP3A4—Gefitinib—lung cancer	0.00652	0.0184	CbGbCtD
Irbesartan—CYP3A4—Teniposide—lung cancer	0.00632	0.0178	CbGbCtD
Irbesartan—CYP2C9—Paclitaxel—lung cancer	0.00607	0.0171	CbGbCtD
Irbesartan—CYP2D6—Erlotinib—lung cancer	0.00606	0.0171	CbGbCtD
Irbesartan—CYP1A2—Etoposide—lung cancer	0.00532	0.015	CbGbCtD
Irbesartan—CYP3A4—Vinorelbine—lung cancer	0.00502	0.0141	CbGbCtD
Irbesartan—CYP2C9—Cisplatin—lung cancer	0.00488	0.0137	CbGbCtD
Irbesartan—CYP2D6—Vinblastine—lung cancer	0.00486	0.0137	CbGbCtD
Irbesartan—CYP3A4—Crizotinib—lung cancer	0.00399	0.0113	CbGbCtD
Irbesartan—CYP3A4—Erlotinib—lung cancer	0.00385	0.0109	CbGbCtD
Irbesartan—CYP3A4—Paclitaxel—lung cancer	0.00353	0.00994	CbGbCtD
Irbesartan—CYP3A4—Irinotecan—lung cancer	0.00348	0.0098	CbGbCtD
Irbesartan—CYP3A4—Vinblastine—lung cancer	0.00309	0.00872	CbGbCtD
Irbesartan—CYP2D6—Doxorubicin—lung cancer	0.00299	0.00842	CbGbCtD
Irbesartan—CYP3A4—Etoposide—lung cancer	0.00279	0.00785	CbGbCtD
Irbesartan—CYP3A4—Docetaxel—lung cancer	0.00255	0.00718	CbGbCtD
Irbesartan—CYP3A4—Doxorubicin—lung cancer	0.0019	0.00536	CbGbCtD
Irbesartan—EDNRA—mammary gland—lung cancer	0.00187	0.0931	CbGeAlD
Irbesartan—JUN—mammary gland—lung cancer	0.00171	0.0849	CbGeAlD
Irbesartan—JUN—respiratory system—lung cancer	0.00114	0.0566	CbGeAlD
Irbesartan—EDNRA—bronchus—lung cancer	0.00103	0.051	CbGeAlD
Irbesartan—JUN—epithelium—lung cancer	0.000952	0.0473	CbGeAlD
Irbesartan—JUN—bronchus—lung cancer	0.000937	0.0466	CbGeAlD
Irbesartan—EDNRA—trachea—lung cancer	0.000922	0.0458	CbGeAlD
Irbesartan—EDNRA—cardiac atrium—lung cancer	0.000866	0.0431	CbGeAlD
Irbesartan—JUN—trachea—lung cancer	0.000842	0.0418	CbGeAlD
Irbesartan—JUN—cardiac atrium—lung cancer	0.000791	0.0393	CbGeAlD
Irbesartan—AGTR1—epithelium—lung cancer	0.000717	0.0356	CbGeAlD
Irbesartan—CYP2C8—mammary gland—lung cancer	0.000698	0.0347	CbGeAlD
Irbesartan—JUN—bone marrow—lung cancer	0.000667	0.0332	CbGeAlD
Irbesartan—EDNRA—lung—lung cancer	0.000663	0.0329	CbGeAlD
Irbesartan—AGTR1—trachea—lung cancer	0.000634	0.0315	CbGeAlD
Irbesartan—CYP2C9—mammary gland—lung cancer	0.00062	0.0308	CbGeAlD
Irbesartan—JUN—lung—lung cancer	0.000605	0.03	CbGeAlD
Irbesartan—AGTR1—cardiac atrium—lung cancer	0.000595	0.0296	CbGeAlD
Irbesartan—Losartan—UGT1A1—lung cancer	0.00049	0.427	CrCbGaD
Irbesartan—AGTR1—lung—lung cancer	0.000455	0.0226	CbGeAlD
Irbesartan—EDNRA—lymph node—lung cancer	0.000453	0.0225	CbGeAlD
Irbesartan—CYP1A2—respiratory system—lung cancer	0.000435	0.0216	CbGeAlD
Irbesartan—JUN—lymph node—lung cancer	0.000414	0.0206	CbGeAlD
Irbesartan—PTGS1—respiratory system—lung cancer	0.000377	0.0187	CbGeAlD
Irbesartan—PTGS1—epithelium—lung cancer	0.000315	0.0157	CbGeAlD
Irbesartan—AGTR1—lymph node—lung cancer	0.000311	0.0155	CbGeAlD
Irbesartan—PTGS1—trachea—lung cancer	0.000279	0.0138	CbGeAlD
Irbesartan—PTGS1—cardiac atrium—lung cancer	0.000262	0.013	CbGeAlD
Irbesartan—Valsartan—ALB—lung cancer	0.000246	0.214	CrCbGaD
Irbesartan—CYP1A2—lung—lung cancer	0.000231	0.0115	CbGeAlD
Irbesartan—PTGS1—lung—lung cancer	0.0002	0.00995	CbGeAlD
Irbesartan—Candesartan—ABCB1—lung cancer	0.000178	0.155	CrCbGaD
Irbesartan—PTGS1—lymph node—lung cancer	0.000137	0.0068	CbGeAlD
Irbesartan—Losartan—ALB—lung cancer	0.00012	0.105	CrCbGaD
Irbesartan—Losartan—ABCB1—lung cancer	0.000115	0.0998	CrCbGaD
Irbesartan—Gastrointestinal disorder—Etoposide—lung cancer	4.46e-05	0.000361	CcSEcCtD
Irbesartan—Dyspepsia—Paclitaxel—lung cancer	4.46e-05	0.000361	CcSEcCtD
Irbesartan—Body temperature increased—Cisplatin—lung cancer	4.46e-05	0.000361	CcSEcCtD
Irbesartan—Asthenia—Irinotecan—lung cancer	4.45e-05	0.000361	CcSEcCtD
Irbesartan—Fatigue—Etoposide—lung cancer	4.45e-05	0.000361	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	4.45e-05	0.00036	CcSEcCtD
Irbesartan—Pain—Etoposide—lung cancer	4.42e-05	0.000358	CcSEcCtD
Irbesartan—Constipation—Etoposide—lung cancer	4.42e-05	0.000358	CcSEcCtD
Irbesartan—Neutropenia—Doxorubicin—lung cancer	4.4e-05	0.000357	CcSEcCtD
Irbesartan—Decreased appetite—Paclitaxel—lung cancer	4.4e-05	0.000357	CcSEcCtD
Irbesartan—Dry mouth—Docetaxel—lung cancer	4.38e-05	0.000355	CcSEcCtD
Irbesartan—Upper respiratory tract infection—Doxorubicin—lung cancer	4.38e-05	0.000355	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Paclitaxel—lung cancer	4.37e-05	0.000354	CcSEcCtD
Irbesartan—Fatigue—Paclitaxel—lung cancer	4.36e-05	0.000354	CcSEcCtD
Irbesartan—Hepatitis—Methotrexate—lung cancer	4.35e-05	0.000353	CcSEcCtD
Irbesartan—Asthenia—Gemcitabine—lung cancer	4.34e-05	0.000351	CcSEcCtD
Irbesartan—Constipation—Paclitaxel—lung cancer	4.33e-05	0.000351	CcSEcCtD
Irbesartan—Pain—Paclitaxel—lung cancer	4.33e-05	0.000351	CcSEcCtD
Irbesartan—Pharyngitis—Methotrexate—lung cancer	4.32e-05	0.00035	CcSEcCtD
Irbesartan—Urinary tract disorder—Methotrexate—lung cancer	4.3e-05	0.000348	CcSEcCtD
Irbesartan—Photosensitivity reaction—Doxorubicin—lung cancer	4.3e-05	0.000348	CcSEcCtD
Irbesartan—Oedema—Docetaxel—lung cancer	4.29e-05	0.000348	CcSEcCtD
Irbesartan—Anaphylactic shock—Docetaxel—lung cancer	4.29e-05	0.000348	CcSEcCtD
Irbesartan—Weight increased—Doxorubicin—lung cancer	4.29e-05	0.000347	CcSEcCtD
Irbesartan—Pruritus—Gemcitabine—lung cancer	4.28e-05	0.000347	CcSEcCtD
Irbesartan—Urethral disorder—Methotrexate—lung cancer	4.27e-05	0.000346	CcSEcCtD
Irbesartan—Infection—Docetaxel—lung cancer	4.26e-05	0.000345	CcSEcCtD
Irbesartan—Feeling abnormal—Etoposide—lung cancer	4.25e-05	0.000345	CcSEcCtD
Irbesartan—Hyperglycaemia—Doxorubicin—lung cancer	4.25e-05	0.000344	CcSEcCtD
Irbesartan—Diarrhoea—Irinotecan—lung cancer	4.25e-05	0.000344	CcSEcCtD
Irbesartan—Pneumonia—Doxorubicin—lung cancer	4.22e-05	0.000342	CcSEcCtD
Irbesartan—Gastrointestinal pain—Etoposide—lung cancer	4.22e-05	0.000342	CcSEcCtD
Irbesartan—Shock—Docetaxel—lung cancer	4.22e-05	0.000342	CcSEcCtD
Irbesartan—Nervous system disorder—Docetaxel—lung cancer	4.21e-05	0.000341	CcSEcCtD
Irbesartan—Thrombocytopenia—Docetaxel—lung cancer	4.2e-05	0.00034	CcSEcCtD
Irbesartan—Visual impairment—Methotrexate—lung cancer	4.2e-05	0.00034	CcSEcCtD
Irbesartan—Tachycardia—Docetaxel—lung cancer	4.19e-05	0.000339	CcSEcCtD
Irbesartan—Feeling abnormal—Paclitaxel—lung cancer	4.17e-05	0.000338	CcSEcCtD
Irbesartan—Skin disorder—Docetaxel—lung cancer	4.17e-05	0.000338	CcSEcCtD
Irbesartan—Hypersensitivity—Cisplatin—lung cancer	4.15e-05	0.000336	CcSEcCtD
Irbesartan—Gastrointestinal pain—Paclitaxel—lung cancer	4.14e-05	0.000335	CcSEcCtD
Irbesartan—Diarrhoea—Gemcitabine—lung cancer	4.14e-05	0.000335	CcSEcCtD
Irbesartan—Renal failure—Doxorubicin—lung cancer	4.13e-05	0.000334	CcSEcCtD
Irbesartan—Dizziness—Irinotecan—lung cancer	4.1e-05	0.000333	CcSEcCtD
Irbesartan—Urticaria—Etoposide—lung cancer	4.1e-05	0.000332	CcSEcCtD
Irbesartan—Jaundice—Doxorubicin—lung cancer	4.09e-05	0.000332	CcSEcCtD
Irbesartan—Anorexia—Docetaxel—lung cancer	4.09e-05	0.000331	CcSEcCtD
Irbesartan—Abdominal pain—Etoposide—lung cancer	4.08e-05	0.000331	CcSEcCtD
Irbesartan—Body temperature increased—Etoposide—lung cancer	4.08e-05	0.000331	CcSEcCtD
Irbesartan—Conjunctivitis—Doxorubicin—lung cancer	4.08e-05	0.000331	CcSEcCtD
Irbesartan—Urinary tract infection—Doxorubicin—lung cancer	4.08e-05	0.000331	CcSEcCtD
Irbesartan—Tinnitus—Methotrexate—lung cancer	4.06e-05	0.000329	CcSEcCtD
Irbesartan—Asthenia—Cisplatin—lung cancer	4.04e-05	0.000328	CcSEcCtD
Irbesartan—Cardiac disorder—Methotrexate—lung cancer	4.04e-05	0.000327	CcSEcCtD
Irbesartan—Urticaria—Paclitaxel—lung cancer	4.02e-05	0.000326	CcSEcCtD
Irbesartan—Hypotension—Docetaxel—lung cancer	4.01e-05	0.000325	CcSEcCtD
Irbesartan—Abdominal pain—Paclitaxel—lung cancer	4e-05	0.000324	CcSEcCtD
Irbesartan—Body temperature increased—Paclitaxel—lung cancer	4e-05	0.000324	CcSEcCtD
Irbesartan—Hepatobiliary disease—Doxorubicin—lung cancer	3.97e-05	0.000322	CcSEcCtD
Irbesartan—Epistaxis—Doxorubicin—lung cancer	3.96e-05	0.000321	CcSEcCtD
Irbesartan—Angiopathy—Methotrexate—lung cancer	3.95e-05	0.00032	CcSEcCtD
Irbesartan—Vomiting—Irinotecan—lung cancer	3.95e-05	0.00032	CcSEcCtD
Irbesartan—Immune system disorder—Methotrexate—lung cancer	3.93e-05	0.000319	CcSEcCtD
Irbesartan—Mediastinal disorder—Methotrexate—lung cancer	3.92e-05	0.000318	CcSEcCtD
Irbesartan—Agranulocytosis—Doxorubicin—lung cancer	3.92e-05	0.000317	CcSEcCtD
Irbesartan—Rash—Irinotecan—lung cancer	3.91e-05	0.000317	CcSEcCtD
Irbesartan—Dermatitis—Irinotecan—lung cancer	3.91e-05	0.000317	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Docetaxel—lung cancer	3.91e-05	0.000317	CcSEcCtD
Irbesartan—Chills—Methotrexate—lung cancer	3.91e-05	0.000316	CcSEcCtD
Irbesartan—Headache—Irinotecan—lung cancer	3.89e-05	0.000315	CcSEcCtD
Irbesartan—Diarrhoea—Cisplatin—lung cancer	3.86e-05	0.000312	CcSEcCtD
Irbesartan—Paraesthesia—Docetaxel—lung cancer	3.85e-05	0.000312	CcSEcCtD
Irbesartan—Vomiting—Gemcitabine—lung cancer	3.84e-05	0.000311	CcSEcCtD
Irbesartan—Bradycardia—Doxorubicin—lung cancer	3.84e-05	0.000311	CcSEcCtD
Irbesartan—Dyspnoea—Docetaxel—lung cancer	3.83e-05	0.00031	CcSEcCtD
Irbesartan—Somnolence—Docetaxel—lung cancer	3.81e-05	0.000309	CcSEcCtD
Irbesartan—Rash—Gemcitabine—lung cancer	3.81e-05	0.000309	CcSEcCtD
Irbesartan—Dermatitis—Gemcitabine—lung cancer	3.81e-05	0.000309	CcSEcCtD
Irbesartan—Hypersensitivity—Etoposide—lung cancer	3.8e-05	0.000308	CcSEcCtD
Irbesartan—Malnutrition—Methotrexate—lung cancer	3.79e-05	0.000307	CcSEcCtD
Irbesartan—Erythema—Methotrexate—lung cancer	3.79e-05	0.000307	CcSEcCtD
Irbesartan—Headache—Gemcitabine—lung cancer	3.79e-05	0.000307	CcSEcCtD
Irbesartan—Rhinitis—Doxorubicin—lung cancer	3.78e-05	0.000306	CcSEcCtD
Irbesartan—Dyspepsia—Docetaxel—lung cancer	3.78e-05	0.000306	CcSEcCtD
Irbesartan—Hepatitis—Doxorubicin—lung cancer	3.77e-05	0.000305	CcSEcCtD
Irbesartan—Hypoaesthesia—Doxorubicin—lung cancer	3.75e-05	0.000304	CcSEcCtD
Irbesartan—Pharyngitis—Doxorubicin—lung cancer	3.74e-05	0.000303	CcSEcCtD
Irbesartan—Decreased appetite—Docetaxel—lung cancer	3.73e-05	0.000302	CcSEcCtD
Irbesartan—Hypersensitivity—Paclitaxel—lung cancer	3.73e-05	0.000302	CcSEcCtD
Irbesartan—Urinary tract disorder—Doxorubicin—lung cancer	3.72e-05	0.000302	CcSEcCtD
Irbesartan—Oedema peripheral—Doxorubicin—lung cancer	3.71e-05	0.000301	CcSEcCtD
Irbesartan—Dysgeusia—Methotrexate—lung cancer	3.71e-05	0.000301	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Docetaxel—lung cancer	3.7e-05	0.0003	CcSEcCtD
Irbesartan—Asthenia—Etoposide—lung cancer	3.7e-05	0.0003	CcSEcCtD
Irbesartan—Connective tissue disorder—Doxorubicin—lung cancer	3.7e-05	0.0003	CcSEcCtD
Irbesartan—Fatigue—Docetaxel—lung cancer	3.7e-05	0.0003	CcSEcCtD
Irbesartan—Urethral disorder—Doxorubicin—lung cancer	3.7e-05	0.000299	CcSEcCtD
Irbesartan—Nausea—Irinotecan—lung cancer	3.69e-05	0.000299	CcSEcCtD
Irbesartan—Pain—Docetaxel—lung cancer	3.67e-05	0.000297	CcSEcCtD
Irbesartan—Constipation—Docetaxel—lung cancer	3.67e-05	0.000297	CcSEcCtD
Irbesartan—Pruritus—Etoposide—lung cancer	3.65e-05	0.000296	CcSEcCtD
Irbesartan—Visual impairment—Doxorubicin—lung cancer	3.63e-05	0.000294	CcSEcCtD
Irbesartan—Asthenia—Paclitaxel—lung cancer	3.63e-05	0.000294	CcSEcCtD
Irbesartan—Nausea—Gemcitabine—lung cancer	3.59e-05	0.000291	CcSEcCtD
Irbesartan—Vomiting—Cisplatin—lung cancer	3.58e-05	0.00029	CcSEcCtD
Irbesartan—Pruritus—Paclitaxel—lung cancer	3.58e-05	0.00029	CcSEcCtD
Irbesartan—Vision blurred—Methotrexate—lung cancer	3.57e-05	0.000289	CcSEcCtD
Irbesartan—Rash—Cisplatin—lung cancer	3.55e-05	0.000288	CcSEcCtD
Irbesartan—Dermatitis—Cisplatin—lung cancer	3.55e-05	0.000288	CcSEcCtD
Irbesartan—Feeling abnormal—Docetaxel—lung cancer	3.54e-05	0.000286	CcSEcCtD
Irbesartan—Diarrhoea—Etoposide—lung cancer	3.53e-05	0.000286	CcSEcCtD
Irbesartan—Ill-defined disorder—Methotrexate—lung cancer	3.52e-05	0.000285	CcSEcCtD
Irbesartan—Tinnitus—Doxorubicin—lung cancer	3.51e-05	0.000285	CcSEcCtD
Irbesartan—Gastrointestinal pain—Docetaxel—lung cancer	3.51e-05	0.000284	CcSEcCtD
Irbesartan—Anaemia—Methotrexate—lung cancer	3.5e-05	0.000284	CcSEcCtD
Irbesartan—Flushing—Doxorubicin—lung cancer	3.5e-05	0.000283	CcSEcCtD
Irbesartan—Cardiac disorder—Doxorubicin—lung cancer	3.5e-05	0.000283	CcSEcCtD
Irbesartan—Diarrhoea—Paclitaxel—lung cancer	3.46e-05	0.000281	CcSEcCtD
Irbesartan—Angiopathy—Doxorubicin—lung cancer	3.42e-05	0.000277	CcSEcCtD
Irbesartan—Malaise—Methotrexate—lung cancer	3.42e-05	0.000277	CcSEcCtD
Irbesartan—Dizziness—Etoposide—lung cancer	3.41e-05	0.000277	CcSEcCtD
Irbesartan—Immune system disorder—Doxorubicin—lung cancer	3.4e-05	0.000276	CcSEcCtD
Irbesartan—Vertigo—Methotrexate—lung cancer	3.4e-05	0.000276	CcSEcCtD
Irbesartan—Mediastinal disorder—Doxorubicin—lung cancer	3.4e-05	0.000275	CcSEcCtD
Irbesartan—Body temperature increased—Docetaxel—lung cancer	3.39e-05	0.000275	CcSEcCtD
Irbesartan—Abdominal pain—Docetaxel—lung cancer	3.39e-05	0.000275	CcSEcCtD
Irbesartan—Leukopenia—Methotrexate—lung cancer	3.39e-05	0.000275	CcSEcCtD
Irbesartan—Chills—Doxorubicin—lung cancer	3.38e-05	0.000274	CcSEcCtD
Irbesartan—Arrhythmia—Doxorubicin—lung cancer	3.37e-05	0.000273	CcSEcCtD
Irbesartan—Dizziness—Paclitaxel—lung cancer	3.35e-05	0.000271	CcSEcCtD
Irbesartan—Nausea—Cisplatin—lung cancer	3.35e-05	0.000271	CcSEcCtD
Irbesartan—Cough—Methotrexate—lung cancer	3.31e-05	0.000268	CcSEcCtD
Irbesartan—Vomiting—Etoposide—lung cancer	3.28e-05	0.000266	CcSEcCtD
Irbesartan—Erythema—Doxorubicin—lung cancer	3.28e-05	0.000266	CcSEcCtD
Irbesartan—Malnutrition—Doxorubicin—lung cancer	3.28e-05	0.000266	CcSEcCtD
Irbesartan—Rash—Etoposide—lung cancer	3.26e-05	0.000264	CcSEcCtD
Irbesartan—Dermatitis—Etoposide—lung cancer	3.25e-05	0.000263	CcSEcCtD
Irbesartan—Headache—Etoposide—lung cancer	3.23e-05	0.000262	CcSEcCtD
Irbesartan—Flatulence—Doxorubicin—lung cancer	3.23e-05	0.000262	CcSEcCtD
Irbesartan—Arthralgia—Methotrexate—lung cancer	3.23e-05	0.000261	CcSEcCtD
Irbesartan—Chest pain—Methotrexate—lung cancer	3.23e-05	0.000261	CcSEcCtD
Irbesartan—Myalgia—Methotrexate—lung cancer	3.23e-05	0.000261	CcSEcCtD
Irbesartan—Tension—Doxorubicin—lung cancer	3.22e-05	0.000261	CcSEcCtD
Irbesartan—Vomiting—Paclitaxel—lung cancer	3.22e-05	0.000261	CcSEcCtD
Irbesartan—Dysgeusia—Doxorubicin—lung cancer	3.21e-05	0.00026	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	3.2e-05	0.00026	CcSEcCtD
Irbesartan—Rash—Paclitaxel—lung cancer	3.19e-05	0.000259	CcSEcCtD
Irbesartan—Dermatitis—Paclitaxel—lung cancer	3.19e-05	0.000258	CcSEcCtD
Irbesartan—Discomfort—Methotrexate—lung cancer	3.19e-05	0.000258	CcSEcCtD
Irbesartan—Nervousness—Doxorubicin—lung cancer	3.19e-05	0.000258	CcSEcCtD
Irbesartan—Headache—Paclitaxel—lung cancer	3.17e-05	0.000257	CcSEcCtD
Irbesartan—Hypersensitivity—Docetaxel—lung cancer	3.16e-05	0.000256	CcSEcCtD
Irbesartan—Muscle spasms—Doxorubicin—lung cancer	3.15e-05	0.000256	CcSEcCtD
Irbesartan—Anaphylactic shock—Methotrexate—lung cancer	3.09e-05	0.000251	CcSEcCtD
Irbesartan—Vision blurred—Doxorubicin—lung cancer	3.09e-05	0.000251	CcSEcCtD
Irbesartan—Asthenia—Docetaxel—lung cancer	3.08e-05	0.000249	CcSEcCtD
Irbesartan—Infection—Methotrexate—lung cancer	3.07e-05	0.000249	CcSEcCtD
Irbesartan—Nausea—Etoposide—lung cancer	3.07e-05	0.000248	CcSEcCtD
Irbesartan—Ill-defined disorder—Doxorubicin—lung cancer	3.04e-05	0.000247	CcSEcCtD
Irbesartan—Pruritus—Docetaxel—lung cancer	3.04e-05	0.000246	CcSEcCtD
Irbesartan—Nervous system disorder—Methotrexate—lung cancer	3.03e-05	0.000246	CcSEcCtD
Irbesartan—Anaemia—Doxorubicin—lung cancer	3.03e-05	0.000246	CcSEcCtD
Irbesartan—Thrombocytopenia—Methotrexate—lung cancer	3.03e-05	0.000245	CcSEcCtD
Irbesartan—Agitation—Doxorubicin—lung cancer	3.02e-05	0.000244	CcSEcCtD
Irbesartan—Nausea—Paclitaxel—lung cancer	3.01e-05	0.000244	CcSEcCtD
Irbesartan—Skin disorder—Methotrexate—lung cancer	3e-05	0.000243	CcSEcCtD
Irbesartan—Hyperhidrosis—Methotrexate—lung cancer	2.99e-05	0.000242	CcSEcCtD
Irbesartan—Malaise—Doxorubicin—lung cancer	2.96e-05	0.00024	CcSEcCtD
Irbesartan—Vertigo—Doxorubicin—lung cancer	2.95e-05	0.000239	CcSEcCtD
Irbesartan—Anorexia—Methotrexate—lung cancer	2.95e-05	0.000239	CcSEcCtD
Irbesartan—Syncope—Doxorubicin—lung cancer	2.94e-05	0.000238	CcSEcCtD
Irbesartan—Leukopenia—Doxorubicin—lung cancer	2.94e-05	0.000238	CcSEcCtD
Irbesartan—Diarrhoea—Docetaxel—lung cancer	2.94e-05	0.000238	CcSEcCtD
Irbesartan—Hypotension—Methotrexate—lung cancer	2.89e-05	0.000234	CcSEcCtD
Irbesartan—Loss of consciousness—Doxorubicin—lung cancer	2.88e-05	0.000234	CcSEcCtD
Irbesartan—Cough—Doxorubicin—lung cancer	2.86e-05	0.000232	CcSEcCtD
Irbesartan—Dizziness—Docetaxel—lung cancer	2.84e-05	0.00023	CcSEcCtD
Irbesartan—Hypertension—Doxorubicin—lung cancer	2.83e-05	0.00023	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Methotrexate—lung cancer	2.82e-05	0.000228	CcSEcCtD
Irbesartan—Arthralgia—Doxorubicin—lung cancer	2.79e-05	0.000226	CcSEcCtD
Irbesartan—Myalgia—Doxorubicin—lung cancer	2.79e-05	0.000226	CcSEcCtD
Irbesartan—Chest pain—Doxorubicin—lung cancer	2.79e-05	0.000226	CcSEcCtD
Irbesartan—Anxiety—Doxorubicin—lung cancer	2.78e-05	0.000226	CcSEcCtD
Irbesartan—Paraesthesia—Methotrexate—lung cancer	2.78e-05	0.000225	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	2.77e-05	0.000225	CcSEcCtD
Irbesartan—Discomfort—Doxorubicin—lung cancer	2.76e-05	0.000224	CcSEcCtD
Irbesartan—Dyspnoea—Methotrexate—lung cancer	2.76e-05	0.000223	CcSEcCtD
Irbesartan—Somnolence—Methotrexate—lung cancer	2.75e-05	0.000223	CcSEcCtD
Irbesartan—Dry mouth—Doxorubicin—lung cancer	2.73e-05	0.000221	CcSEcCtD
Irbesartan—Vomiting—Docetaxel—lung cancer	2.73e-05	0.000221	CcSEcCtD
Irbesartan—Dyspepsia—Methotrexate—lung cancer	2.72e-05	0.000221	CcSEcCtD
Irbesartan—Rash—Docetaxel—lung cancer	2.71e-05	0.000219	CcSEcCtD
Irbesartan—Dermatitis—Docetaxel—lung cancer	2.7e-05	0.000219	CcSEcCtD
Irbesartan—Decreased appetite—Methotrexate—lung cancer	2.69e-05	0.000218	CcSEcCtD
Irbesartan—Headache—Docetaxel—lung cancer	2.69e-05	0.000218	CcSEcCtD
Irbesartan—Oedema—Doxorubicin—lung cancer	2.68e-05	0.000217	CcSEcCtD
Irbesartan—Anaphylactic shock—Doxorubicin—lung cancer	2.68e-05	0.000217	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Methotrexate—lung cancer	2.67e-05	0.000216	CcSEcCtD
Irbesartan—Fatigue—Methotrexate—lung cancer	2.67e-05	0.000216	CcSEcCtD
Irbesartan—Infection—Doxorubicin—lung cancer	2.66e-05	0.000216	CcSEcCtD
Irbesartan—Pain—Methotrexate—lung cancer	2.64e-05	0.000214	CcSEcCtD
Irbesartan—Shock—Doxorubicin—lung cancer	2.63e-05	0.000213	CcSEcCtD
Irbesartan—Nervous system disorder—Doxorubicin—lung cancer	2.63e-05	0.000213	CcSEcCtD
Irbesartan—Thrombocytopenia—Doxorubicin—lung cancer	2.62e-05	0.000212	CcSEcCtD
Irbesartan—Tachycardia—Doxorubicin—lung cancer	2.61e-05	0.000212	CcSEcCtD
Irbesartan—Skin disorder—Doxorubicin—lung cancer	2.6e-05	0.000211	CcSEcCtD
Irbesartan—Hyperhidrosis—Doxorubicin—lung cancer	2.59e-05	0.00021	CcSEcCtD
Irbesartan—Anorexia—Doxorubicin—lung cancer	2.55e-05	0.000207	CcSEcCtD
Irbesartan—Nausea—Docetaxel—lung cancer	2.55e-05	0.000206	CcSEcCtD
Irbesartan—Feeling abnormal—Methotrexate—lung cancer	2.55e-05	0.000206	CcSEcCtD
Irbesartan—Gastrointestinal pain—Methotrexate—lung cancer	2.53e-05	0.000205	CcSEcCtD
Irbesartan—Hypotension—Doxorubicin—lung cancer	2.5e-05	0.000203	CcSEcCtD
Irbesartan—Urticaria—Methotrexate—lung cancer	2.46e-05	0.000199	CcSEcCtD
Irbesartan—Body temperature increased—Methotrexate—lung cancer	2.44e-05	0.000198	CcSEcCtD
Irbesartan—Abdominal pain—Methotrexate—lung cancer	2.44e-05	0.000198	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Doxorubicin—lung cancer	2.44e-05	0.000198	CcSEcCtD
Irbesartan—Paraesthesia—Doxorubicin—lung cancer	2.4e-05	0.000195	CcSEcCtD
Irbesartan—Dyspnoea—Doxorubicin—lung cancer	2.39e-05	0.000193	CcSEcCtD
Irbesartan—Somnolence—Doxorubicin—lung cancer	2.38e-05	0.000193	CcSEcCtD
Irbesartan—Dyspepsia—Doxorubicin—lung cancer	2.36e-05	0.000191	CcSEcCtD
Irbesartan—Decreased appetite—Doxorubicin—lung cancer	2.33e-05	0.000189	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Doxorubicin—lung cancer	2.31e-05	0.000187	CcSEcCtD
Irbesartan—Fatigue—Doxorubicin—lung cancer	2.31e-05	0.000187	CcSEcCtD
Irbesartan—Constipation—Doxorubicin—lung cancer	2.29e-05	0.000186	CcSEcCtD
Irbesartan—Pain—Doxorubicin—lung cancer	2.29e-05	0.000186	CcSEcCtD
Irbesartan—Hypersensitivity—Methotrexate—lung cancer	2.28e-05	0.000185	CcSEcCtD
Irbesartan—Asthenia—Methotrexate—lung cancer	2.22e-05	0.00018	CcSEcCtD
Irbesartan—Feeling abnormal—Doxorubicin—lung cancer	2.21e-05	0.000179	CcSEcCtD
Irbesartan—Gastrointestinal pain—Doxorubicin—lung cancer	2.19e-05	0.000177	CcSEcCtD
Irbesartan—Pruritus—Methotrexate—lung cancer	2.19e-05	0.000177	CcSEcCtD
Irbesartan—Urticaria—Doxorubicin—lung cancer	2.13e-05	0.000172	CcSEcCtD
Irbesartan—Abdominal pain—Doxorubicin—lung cancer	2.12e-05	0.000172	CcSEcCtD
Irbesartan—Body temperature increased—Doxorubicin—lung cancer	2.12e-05	0.000172	CcSEcCtD
Irbesartan—Diarrhoea—Methotrexate—lung cancer	2.12e-05	0.000171	CcSEcCtD
Irbesartan—Dizziness—Methotrexate—lung cancer	2.05e-05	0.000166	CcSEcCtD
Irbesartan—Hypersensitivity—Doxorubicin—lung cancer	1.97e-05	0.00016	CcSEcCtD
Irbesartan—Vomiting—Methotrexate—lung cancer	1.97e-05	0.000159	CcSEcCtD
Irbesartan—Rash—Methotrexate—lung cancer	1.95e-05	0.000158	CcSEcCtD
Irbesartan—Dermatitis—Methotrexate—lung cancer	1.95e-05	0.000158	CcSEcCtD
Irbesartan—Headache—Methotrexate—lung cancer	1.94e-05	0.000157	CcSEcCtD
Irbesartan—Asthenia—Doxorubicin—lung cancer	1.92e-05	0.000156	CcSEcCtD
Irbesartan—Pruritus—Doxorubicin—lung cancer	1.89e-05	0.000153	CcSEcCtD
Irbesartan—Nausea—Methotrexate—lung cancer	1.84e-05	0.000149	CcSEcCtD
Irbesartan—Diarrhoea—Doxorubicin—lung cancer	1.83e-05	0.000148	CcSEcCtD
Irbesartan—Dizziness—Doxorubicin—lung cancer	1.77e-05	0.000143	CcSEcCtD
Irbesartan—Vomiting—Doxorubicin—lung cancer	1.7e-05	0.000138	CcSEcCtD
Irbesartan—Rash—Doxorubicin—lung cancer	1.69e-05	0.000137	CcSEcCtD
Irbesartan—Dermatitis—Doxorubicin—lung cancer	1.69e-05	0.000137	CcSEcCtD
Irbesartan—Headache—Doxorubicin—lung cancer	1.68e-05	0.000136	CcSEcCtD
Irbesartan—Nausea—Doxorubicin—lung cancer	1.59e-05	0.000129	CcSEcCtD
Irbesartan—CYP2C9—Metabolism—GSTT1—lung cancer	3.47e-06	3.25e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	3.47e-06	3.25e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CREBBP—lung cancer	3.47e-06	3.25e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GNG11—lung cancer	3.47e-06	3.25e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CYP2A6—lung cancer	3.46e-06	3.24e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GCLC—lung cancer	3.46e-06	3.24e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—lung cancer	3.45e-06	3.23e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	3.44e-06	3.22e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CCND1—lung cancer	3.43e-06	3.22e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—EGFR—lung cancer	3.43e-06	3.22e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GCLC—lung cancer	3.43e-06	3.21e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CYP2A6—lung cancer	3.43e-06	3.21e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—JUN—lung cancer	3.43e-06	3.21e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—STAT3—lung cancer	3.43e-06	3.21e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—APOA1—lung cancer	3.42e-06	3.21e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	3.42e-06	3.2e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—NRAS—lung cancer	3.42e-06	3.2e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MMP9—lung cancer	3.33e-06	3.12e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CDKN1A—lung cancer	3.32e-06	3.11e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PTEN—lung cancer	3.31e-06	3.11e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MAP2K1—lung cancer	3.31e-06	3.1e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ALDOA—lung cancer	3.3e-06	3.09e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PIK3CD—lung cancer	3.29e-06	3.08e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ENO1—lung cancer	3.28e-06	3.07e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	3.27e-06	3.07e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—MAPK3—lung cancer	3.27e-06	3.07e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—B4GALT5—lung cancer	3.26e-06	3.06e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ENO1—lung cancer	3.25e-06	3.05e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—KRAS—lung cancer	3.24e-06	3.04e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	3.24e-06	3.04e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—AKT1—lung cancer	3.23e-06	3.03e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—NCOA3—lung cancer	3.21e-06	3e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—lung cancer	3.2e-06	3e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—STK11—lung cancer	3.19e-06	2.99e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GSTA4—lung cancer	3.18e-06	2.98e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—EP300—lung cancer	3.16e-06	2.96e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—lung cancer	3.15e-06	2.95e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PIK3CG—lung cancer	3.12e-06	2.93e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ADCY1—lung cancer	3.12e-06	2.92e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ABCG2—lung cancer	3.12e-06	2.92e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—EGFR—lung cancer	3.11e-06	2.92e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GSTA2—lung cancer	3.09e-06	2.9e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—SRC—lung cancer	3.07e-06	2.88e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—HPGDS—lung cancer	3.06e-06	2.87e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ENO2—lung cancer	3.06e-06	2.87e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PPP2R1B—lung cancer	3.04e-06	2.85e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—lung cancer	3e-06	2.81e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—POMC—lung cancer	3e-06	2.81e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—VEGFA—lung cancer	2.99e-06	2.81e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GSTA1—lung cancer	2.99e-06	2.8e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—PIK3CA—lung cancer	2.98e-06	2.79e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—POMC—lung cancer	2.97e-06	2.79e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GSTT1—lung cancer	2.97e-06	2.78e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—STAT3—lung cancer	2.96e-06	2.78e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—NRAS—lung cancer	2.96e-06	2.77e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GSTP1—lung cancer	2.96e-06	2.77e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ABCC3—lung cancer	2.95e-06	2.77e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MDM2—lung cancer	2.95e-06	2.76e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CYP2E1—lung cancer	2.94e-06	2.76e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—KRAS—lung cancer	2.94e-06	2.76e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—RAF1—lung cancer	2.94e-06	2.75e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GCLC—lung cancer	2.93e-06	2.75e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CYP2A6—lung cancer	2.93e-06	2.75e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	2.92e-06	2.74e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CYP2E1—lung cancer	2.92e-06	2.73e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—NQO1—lung cancer	2.91e-06	2.73e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—ERBB2—lung cancer	2.9e-06	2.72e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—CREBBP—lung cancer	2.89e-06	2.71e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—NQO1—lung cancer	2.88e-06	2.7e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TP53—lung cancer	2.88e-06	2.7e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CAT—lung cancer	2.88e-06	2.7e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PIK3CB—lung cancer	2.87e-06	2.69e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MTOR—lung cancer	2.87e-06	2.69e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—EP300—lung cancer	2.86e-06	2.68e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—AKR1C1—lung cancer	2.86e-06	2.68e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MAPK3—lung cancer	2.83e-06	2.65e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	2.82e-06	2.65e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	2.8e-06	2.62e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ABCB1—lung cancer	2.8e-06	2.62e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ENO1—lung cancer	2.78e-06	2.6e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—UGT1A1—lung cancer	2.78e-06	2.6e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	2.77e-06	2.59e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—HRAS—lung cancer	2.76e-06	2.58e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MYC—lung cancer	2.75e-06	2.58e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CXCL8—lung cancer	2.75e-06	2.58e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—TYMS—lung cancer	2.75e-06	2.58e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PIK3CD—lung cancer	2.74e-06	2.57e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—ALB—lung cancer	2.73e-06	2.56e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GSTM1—lung cancer	2.72e-06	2.55e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—ALB—lung cancer	2.71e-06	2.54e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—PIK3CA—lung cancer	2.7e-06	2.53e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—EGFR—lung cancer	2.69e-06	2.52e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GNG11—lung cancer	2.68e-06	2.51e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—IL6—lung cancer	2.64e-06	2.47e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CASP3—lung cancer	2.64e-06	2.47e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IL2—lung cancer	2.63e-06	2.47e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—STK11—lung cancer	2.62e-06	2.46e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—STK11—lung cancer	2.6e-06	2.44e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PIK3CA—lung cancer	2.59e-06	2.43e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CYP1A1—lung cancer	2.57e-06	2.41e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CCND1—lung cancer	2.57e-06	2.4e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ERCC2—lung cancer	2.55e-06	2.39e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ALDOA—lung cancer	2.55e-06	2.39e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—KRAS—lung cancer	2.55e-06	2.39e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—HRAS—lung cancer	2.5e-06	2.34e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CYP2E1—lung cancer	2.49e-06	2.34e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MMP9—lung cancer	2.49e-06	2.33e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CDKN1A—lung cancer	2.48e-06	2.33e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PTEN—lung cancer	2.48e-06	2.32e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—NCOA3—lung cancer	2.47e-06	2.32e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—NQO1—lung cancer	2.46e-06	2.31e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—lung cancer	2.44e-06	2.29e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—AKT1—lung cancer	2.43e-06	2.28e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GSTP1—lung cancer	2.43e-06	2.27e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	2.41e-06	2.26e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ADCY1—lung cancer	2.41e-06	2.26e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ABCG2—lung cancer	2.41e-06	2.26e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GSTP1—lung cancer	2.41e-06	2.25e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—IL6—lung cancer	2.39e-06	2.24e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PIK3CB—lung cancer	2.39e-06	2.24e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	2.39e-06	2.24e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PTGS2—lung cancer	2.37e-06	2.22e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—EP300—lung cancer	2.36e-06	2.21e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CAT—lung cancer	2.36e-06	2.21e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ENO2—lung cancer	2.36e-06	2.21e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—HPGDS—lung cancer	2.36e-06	2.21e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PPP2R1B—lung cancer	2.34e-06	2.2e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CAT—lung cancer	2.34e-06	2.19e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PIK3CA—lung cancer	2.34e-06	2.19e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—EP300—lung cancer	2.33e-06	2.18e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ABCB1—lung cancer	2.3e-06	2.15e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—SRC—lung cancer	2.3e-06	2.15e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GSTT1—lung cancer	2.29e-06	2.14e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ABCB1—lung cancer	2.28e-06	2.13e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GCLC—lung cancer	2.26e-06	2.12e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CYP2A6—lung cancer	2.26e-06	2.12e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TP53—lung cancer	2.26e-06	2.12e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—TYMS—lung cancer	2.26e-06	2.11e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—VEGFA—lung cancer	2.24e-06	2.1e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—TYMS—lung cancer	2.24e-06	2.1e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GSTM1—lung cancer	2.23e-06	2.09e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—STK11—lung cancer	2.22e-06	2.08e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—STAT3—lung cancer	2.21e-06	2.08e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GSTM1—lung cancer	2.21e-06	2.07e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—NRAS—lung cancer	2.21e-06	2.07e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—APOA1—lung cancer	2.21e-06	2.07e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—AKT1—lung cancer	2.21e-06	2.07e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—HRAS—lung cancer	2.16e-06	2.03e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ENO1—lung cancer	2.14e-06	2.01e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MAPK3—lung cancer	2.12e-06	1.98e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	2.12e-06	1.98e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—AKT1—lung cancer	2.12e-06	1.98e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CYP1A1—lung cancer	2.11e-06	1.98e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ERCC2—lung cancer	2.1e-06	1.96e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CYP1A1—lung cancer	2.1e-06	1.96e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—lung cancer	2.09e-06	1.95e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ERCC2—lung cancer	2.08e-06	1.95e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—IL6—lung cancer	2.07e-06	1.94e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PTEN—lung cancer	2.07e-06	1.94e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MYC—lung cancer	2.06e-06	1.93e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GSTP1—lung cancer	2.06e-06	1.93e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PIK3CG—lung cancer	2.02e-06	1.89e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—EGFR—lung cancer	2.01e-06	1.89e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CAT—lung cancer	2e-06	1.87e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—EP300—lung cancer	1.99e-06	1.86e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—EP300—lung cancer	1.97e-06	1.85e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ABCB1—lung cancer	1.95e-06	1.82e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CYP2E1—lung cancer	1.92e-06	1.8e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—POMC—lung cancer	1.92e-06	1.8e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—TYMS—lung cancer	1.91e-06	1.79e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—AKT1—lung cancer	1.91e-06	1.79e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—NQO1—lung cancer	1.9e-06	1.78e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—KRAS—lung cancer	1.9e-06	1.78e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GSTM1—lung cancer	1.89e-06	1.77e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CREBBP—lung cancer	1.87e-06	1.75e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—APOA1—lung cancer	1.81e-06	1.7e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—APOA1—lung cancer	1.8e-06	1.68e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CYP1A1—lung cancer	1.79e-06	1.68e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ERCC2—lung cancer	1.78e-06	1.66e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PIK3CD—lung cancer	1.77e-06	1.66e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ALB—lung cancer	1.75e-06	1.64e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PIK3CA—lung cancer	1.75e-06	1.64e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	1.72e-06	1.61e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—STK11—lung cancer	1.71e-06	1.61e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TP53—lung cancer	1.69e-06	1.58e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PIK3CG—lung cancer	1.66e-06	1.55e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PIK3CG—lung cancer	1.64e-06	1.54e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—HRAS—lung cancer	1.62e-06	1.51e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GSTP1—lung cancer	1.59e-06	1.49e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—POMC—lung cancer	1.58e-06	1.48e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—POMC—lung cancer	1.56e-06	1.46e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IL6—lung cancer	1.55e-06	1.45e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PIK3CB—lung cancer	1.55e-06	1.45e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CAT—lung cancer	1.54e-06	1.45e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—APOA1—lung cancer	1.54e-06	1.44e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CREBBP—lung cancer	1.54e-06	1.44e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PTGS2—lung cancer	1.53e-06	1.44e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CREBBP—lung cancer	1.52e-06	1.43e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ABCB1—lung cancer	1.5e-06	1.41e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—TYMS—lung cancer	1.47e-06	1.38e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	1.47e-06	1.38e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PIK3CA—lung cancer	1.46e-06	1.37e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GSTM1—lung cancer	1.46e-06	1.37e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PIK3CD—lung cancer	1.46e-06	1.36e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PIK3CD—lung cancer	1.44e-06	1.35e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ALB—lung cancer	1.44e-06	1.35e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—AKT1—lung cancer	1.43e-06	1.34e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ALB—lung cancer	1.42e-06	1.33e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PIK3CG—lung cancer	1.4e-06	1.31e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CYP1A1—lung cancer	1.38e-06	1.3e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ERCC2—lung cancer	1.37e-06	1.28e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PTEN—lung cancer	1.34e-06	1.25e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—POMC—lung cancer	1.34e-06	1.25e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CREBBP—lung cancer	1.3e-06	1.22e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—EP300—lung cancer	1.27e-06	1.19e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PIK3CB—lung cancer	1.27e-06	1.19e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PIK3CB—lung cancer	1.26e-06	1.18e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PTGS2—lung cancer	1.26e-06	1.18e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PTGS2—lung cancer	1.25e-06	1.17e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PIK3CD—lung cancer	1.23e-06	1.16e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ALB—lung cancer	1.22e-06	1.14e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—AKT1—lung cancer	1.19e-06	1.12e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—APOA1—lung cancer	1.19e-06	1.11e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PTEN—lung cancer	1.1e-06	1.03e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PTEN—lung cancer	1.09e-06	1.02e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PIK3CG—lung cancer	1.08e-06	1.01e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PIK3CB—lung cancer	1.07e-06	1.01e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PTGS2—lung cancer	1.06e-06	9.98e-06	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—EP300—lung cancer	1.05e-06	9.8e-06	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—EP300—lung cancer	1.04e-06	9.71e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—POMC—lung cancer	1.03e-06	9.66e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CREBBP—lung cancer	1e-06	9.41e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PIK3CD—lung cancer	9.52e-07	8.92e-06	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PIK3CA—lung cancer	9.42e-07	8.83e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ALB—lung cancer	9.39e-07	8.8e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PTEN—lung cancer	9.29e-07	8.7e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—EP300—lung cancer	8.86e-07	8.3e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PIK3CB—lung cancer	8.29e-07	7.77e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PTGS2—lung cancer	8.22e-07	7.7e-06	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PIK3CA—lung cancer	7.73e-07	7.25e-06	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—AKT1—lung cancer	7.7e-07	7.21e-06	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PIK3CA—lung cancer	7.67e-07	7.19e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PTEN—lung cancer	7.17e-07	6.72e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—EP300—lung cancer	6.84e-07	6.41e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PIK3CA—lung cancer	6.55e-07	6.14e-06	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—AKT1—lung cancer	6.32e-07	5.92e-06	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—AKT1—lung cancer	6.26e-07	5.87e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—AKT1—lung cancer	5.35e-07	5.02e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PIK3CA—lung cancer	5.06e-07	4.74e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—AKT1—lung cancer	4.13e-07	3.87e-06	CbGpPWpGaD
